Pipeline
Our pipeline is led by RSO-021, which is currently being evaluated in a Phase 2 clinical trial in mesothelioma, and as a combination therapy in metastatic breast cancer, metastatic ovarian cancer, and non-small cell lung cancer.
Our second-generation PRX3 inhibitor, RSO-023, is in preclinical development to evaluate it as a systemic drug for all solid tumors.
ROA
Indication
IND-EnablingPH1PH2PH3
Status
RSO-021
IPC
Metastatic, ovarian and breast cancer with MPE, and Pleural Mesothelioma
INDPH1PH2PH3
TLR mid-2025
RSO-023
Systemic
Solid Tumors
INDPH1PH2PH3
MHRA IND filing early 2026
IPC: intrapleural/intraperitoneal cavity · TLR: top-line results · MHRA: Medicines & Healthcare products Regulatory Agency